EVAX (Evaxion AS) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EVAX Evaxion AS EVAX
48 GF Score
Price $3.52
GF Value $3.34
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Evaxion AS Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

EVAX
48GF Score
Evaxion AS EVAX
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Evaxion AS (EVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Evaxion AS stock appears to be overvalued. The current stock price of $3.52 is trading 5.4% above its estimated GF Value™ of $3.34. GuruFocus considers Evaxion AS to be Fairly Valued.

Key valuation signals for EVAX:

  • Dividends Received:
  • GF Value™: $3.34 vs. price of $3.52 (5.4% above fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the EVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evaxion AS Business Description

Address Dr. Neergaards Vej 5f, Horsholm, DNK, 2970
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
48GF Score

Get the complete analysis for EVAX

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.52
Price
$3.34
GF Value